Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing. These approaches also have considerable potential to limit the use of animals in human drug development. Recent years have witnessed progress in applications, methodology, operations, and drug development culture. Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development. In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity. PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses. Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations. Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures. However, possibly the most challenging domain in which progress has been made, is the culture of drug development. One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of 'kill-early-kill-cheap' to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies. Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Singh, J. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.162004 · Cited by 893
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
Dunne, J., Rodriguez, W. J., Murphy, M. D., Beasley, B. N., Burckart, G. J., Filie, J. D., Lewis, L. L., Sachs, H. C., Sheridan, P. H., Starke, P., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-3487 · Cited by 318
Bergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Research works printed but not linked: 7
- Vuong L.T., 2015, Future Science OA, 2, 1
- Wagner C.C., 2008, Current Opinion in Drug Discovery & Development, 11, 104
- LappinG., WarringtonS., HoneybourneD., SangheraD., DowenS., ListerN., IslamK. & LociuroS. (2007). Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. [Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA].
- Carpenter A.P., 2009, Quarterly Journal of Nuclear Medicine & Molecular Imaging, 53, 387
- Combes R., 2006, ATLA, 34, 621
- BéruBé K., 2009, ATLA, 37, 89
- Bailey J., 2014, ATLA, 42, 181
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Self-citationMonoplex and multiplex immunoassays: approval, advancements, and alternatives
Ahsan, H. (2021) · Comparative Clinical Pathology · doi:10.1007/s00580-021-03302-4 · Cited by 93
Hou, L., Rong, J., Haider, A., Ogasawara, D., Varlow, C., Schafroth, M. A., Mu, L., Gan, J., Xu, H., Fowler, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01459 · Cited by 67
Eke, A. C., Olagunju, A., Best, B. M., Mirochnick, M. H., Momper, J. D., Abrams, E. J., Penazzato, M., Cressey, T. R., & Colbers, A. P. H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00915-w · Cited by 34
Metadata
- Authors
- Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R.
- Affiliations
- Burt Consultancy, LLC, Durham, NC, USA;
- LTV Consulting, Davis, CA, USA;
- Physicians Committee for Responsible Medicine (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Lawrence Livermore National Laboratory (US)
- Department of Pharmacology and PET-centre, Uppsala University, Uppsala, Sweden
- RIKEN (JP)
- Independent Consultant, Norwich, UK
- Corresponding author
- Burt, Tal
- Venue
- Alternatives to Laboratory Animals
- Publisher
- SAGE Publications
- Published
- 2018-12
- Volume
- 46
- Issue
- 6
- Pages
- 335-346
- ISSN
- 0261-1929 (ISSN-L)
- 2632-3559
- OpenAlex
- W2938039109
- Cited by
- 18
- References
- 69
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 2
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Alternatives to Laboratory Animals (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- microdosing, 3Rs, animal testing reduction, positron emission tomography, target engagement, LC-MS/MS, cavity ring-down spectroscopy, pediatric drug development, drug development efficiency
- MeSH terms
- Drug Development, Animals, Animal Testing Alternatives, Animal Welfare, Chromatography, Liquid, Humans, Animal Experimentation, Positron-Emission Tomography, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. https://app.cochat.ai/papers/10.1177/026119291804600603
- The paper
- Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R. (2018). Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. Alternatives to Laboratory Animals. https://doi.org/10.1177/026119291804600603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.